Chordia Therapeutics,Inc (190A) Stock Price

Chordia Therapeutics is a drug discovery venture that researches and develops small-molecule cancer drugs with novel mechanisms of action. The company focuses on creating first-in-class drugs targeting "RNA regulatory stress" in cancer cells, and is advancing clinical-stage candidates including rogocekib (a CLK inhibitor, CTX-712) and a MALT1 inhibitor (CTX-177).

The company's primary customers are major pharmaceutical companies and development partners. Its business model generates revenue through collaborative research and licensing agreements with these partners. Revenue sources include upfront contract payments, development and sales milestones, and future royalties, with near-term revenue expected primarily from partnerships.

The company operates both clinical and preclinical pipelines, with a total of five programs: rogocekib and CTX-177 in clinical development, and CTX-439 (a CDK12 inhibitor), a GCN2 inhibitor, and others in preclinical stages. The company outsources most manufacturing and sales to external partners while accelerating development through collaborations with universities, public institutions, and pharmaceutical companies. Its strategy involves negotiating international sales rights licenses at the Phase 2 stage when asset value increases.

Chordia Therapeutics has adopted a vision to "grow into a Japan-originated research and development-focused pharmaceutical company by 2030," with early commercialization of new drugs as its growth target. Rather than targeting financial metrics such as ROA and ROE, the company positions pipeline progress as its most critical management indicator. Specifically, for its lead candidate rogocekib, the company completed patient enrollment in a domestic Phase I trial in August 2023 and initiated a Phase I/II trial in the United States in 2023. Under its current clinical strategy, leveraging designated programs both domestically and internationally, the company aims for regulatory approval application in late 2028. However, the company continues to face operating losses and negative operating cash flow due to substantial R&D expenses typical of drug discovery ventures, making stable funding procurement an immediate priority.

The company's priority investment area is small-molecule first-in-class cancer drugs, with particular focus on drug candidates targeting "RNA control stress" in cancer cells. Chordia allocates research and development resources primarily to rogocekib (a CLK inhibitor) and CTX-177 (a MALT1 inhibitor) in clinical stages, while maintaining CTX-439 and GCN2 inhibitors in preclinical development, operating a total of five pipeline programs. As a differentiation strategy, the company aims to demonstrate "distinct utility different from existing treatments" through its proprietary mechanisms of action. Simultaneously, it outsources manufacturing and sales to external partners and efficiently allocates resources by leveraging subsidies from universities and public institutions such as AMED.

For market expansion and business growth, the company envisions global regulatory approvals including the United States and Europe, as well as commercialization through licensing agreements with major pharmaceutical companies. The revenue model centers on upfront payments from partnerships, development and sales milestones, and future royalties, with domestic self-commercialization also under consideration. The company has already reached basic agreements on business partnerships and collaborations with Medipal Holdings and Shionogi Pharma. For CTX-177, following the termination of its contract with Ono Pharmaceutical, the company retains worldwide rights and is actively pursuing new licensing partners. The company plans to strengthen its financial foundation through partnerships with business entities and capital procurement via equity issuance as needed.

Regarding technological innovation, the company prioritizes maintaining access to cutting-edge science and external collaboration. Through joint research with academia, utilization of public subsidies, and efficient development structures via outsourcing, the company accelerates research speed while monitoring advances in drug discovery technologies such as AI and computational methods for potential application in exploration and design processes. The company is also advancing the recruitment and development of outstanding researchers and management personnel, with a policy to progressively strengthen its R&D and internal management systems to enhance pipeline success rates and business sustainability.